Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Minority Interest Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Ironwood Pharmaceuticals (IRWD) Short term Debt (2016 - 2026)

Ironwood Pharmaceuticals' Short term Debt history spans 8 years, with the latest figure at $199.7 million for Q4 2025.

On a quarterly basis, Short term Debt changed N/A to $199.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $199.7 million, a N/A change, with the full-year FY2025 number at $199.7 million, changed N/A from a year prior.
Short term Debt hit $199.7 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $199.5 million in the prior quarter.
Over the last five years, Short term Debt for IRWD hit a ceiling of $199.8 million in Q1 2024 and a floor of $112.9 million in Q2 2021.
Historically, Short term Debt has averaged $169.2 million across 5 years, with a median of $199.3 million in 2023.